- Home
- AAT vs SLNO Comparison
AAT vs SLNO Comparison
Compare AAT & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAT
- SLNO
- Stock Information
- Founded
- AAT 1967
- SLNO 1999
- Country
- AAT United States
- SLNO United States
- Employees
- AAT N/A
- SLNO N/A
- Industry
- AAT Real Estate Investment Trusts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AAT Real Estate
- SLNO Health Care
- Exchange
- AAT Nasdaq
- SLNO Nasdaq
- Market Cap
- AAT 1.2B
- SLNO 3.8B
- IPO Year
- AAT 2011
- SLNO 2014
- Fundamental
- Price
- AAT $19.94
- SLNO $85.27
- Analyst Decision
- AAT Hold
- SLNO Strong Buy
- Analyst Count
- AAT 2
- SLNO 9
- Target Price
- AAT $21.00
- SLNO $103.33
- AVG Volume (30 Days)
- AAT 538.8K
- SLNO 1.1M
- Earning Date
- AAT 07-29-2025
- SLNO 08-06-2025
- Dividend Yield
- AAT 6.73%
- SLNO N/A
- EPS Growth
- AAT 49.17
- SLNO N/A
- EPS
- AAT 1.33
- SLNO N/A
- Revenue
- AAT $451,281,000.00
- SLNO N/A
- Revenue This Year
- AAT $1.49
- SLNO N/A
- Revenue Next Year
- AAT N/A
- SLNO N/A
- P/E Ratio
- AAT $15.25
- SLNO N/A
- Revenue Growth
- AAT 2.65
- SLNO N/A
- 52 Week Low
- AAT $16.69
- SLNO $40.67
- 52 Week High
- AAT $29.15
- SLNO $87.16
- Technical
- Relative Strength Index (RSI)
- AAT 49.49
- SLNO 62.75
- Support Level
- AAT $19.43
- SLNO $81.61
- Resistance Level
- AAT $20.45
- SLNO $87.16
- Average True Range (ATR)
- AAT 0.48
- SLNO 3.03
- MACD
- AAT -0.03
- SLNO 0.24
- Stochastic Oscillator
- AAT 42.07
- SLNO 82.85
About AAT American Assets Trust Inc.
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.